Skip to content
Home/Companies/MedTech/ARK Diagnostics

ARK Diagnostics

MedTech·United States·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns ARK Diagnostics?

ARK Diagnostics is an American MedTech company, currently owned by ARCHIMED since 2025.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
ARCHIMED
Investor
ARCHIMED
MED Platform II · 2022 · Buyout

Key facts

HQUnited States
SectorMedTech

More from MED Platform II

Other portfolio companies in the same fund.

Esperion Therapeutics
Active
· 2026
Instem
Instem
Active
HealthTechUS· 2023
Symbio
Symbio
Active
ClimateTechUS· 2023
WiQo
WiQo
Active
HealthTechItaly· 2023
Corealis
Corealis
Active
PharmaCanada· 2022
Natus
Natus
Active
MedTechUS· 2022

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns ARK Diagnostics?

ARK Diagnostics is currently owned by ARCHIMED, through MED Platform II, since 2025.

When did ARCHIMED acquire ARK Diagnostics?

ARCHIMED acquired ARK Diagnostics in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue